Do STAT3 inhibitors have potential in the future for cancer therapy?
Andrea L.A. Wong(National University Cancer Institute, Singapore), Jayshree L. Hirpara(National University Cancer Institute, Singapore), Shazib Pervaiz(National University of Singapore), Jie-Qing Eu(National University Cancer Institute, Singapore), Gautam Sethi(National University of Singapore), Boon-Cher Goh(National University of Singapore)
Cited by 222Open Access
Abstract
10.1080/13543784.2017.1351941
Related Papers
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali et al.|New England Journal of Medicine|2012|1.8k